Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.
52 Week high
52 Week low
Seeking Alpha • 12 days ago • BIIBBiogen Inc. (BIIB) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)
The Motley Fool • 14 days ago • BIIBDoes Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
CNBC Television • 17 days ago • BIIBCall of the day: The health care trade
Market Watch • 17 days ago • BIIBBiogen names Dr. Jane Grogan head of research effective Oct. 2
GlobeNewsWire • 17 days ago • BIIBBiogen Appoints Jane Grogan as Head of Research
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.